Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659288 | 0.93 | TSHR (0.50) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL13375073 | 0.88 | TSHR (0.46) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL5952479 | 0.86 | POLB (0.52) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL13375299 | 0.86 | TSHR (0.47) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL6834085 | 0.85 | MAPT (0.50) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL11267280 | 0.84 | CYP1A2 (0.47) | TSHRMAPTPOLBL3MBTL1HTT | |
| SCHEMBL14659068 | 0.82 | TSHR (0.41) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL6835952 | 0.82 | POLB (0.52) | TSHRMAPTPOLBMEN1KMT2A | |
| SCHEMBL12396038 | 0.82 | TSHR (0.46) | TSHRMAPTPOLBL3MBTL1HTT | |
| SCHEMBL11219818 | 0.82 | TSHR (0.59) | TSHRMAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| EP-2555623-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | TSHR 3828/4885MAPT 3479/4885POLB 2261/4885 |
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | TSHR 3098/4885MAPT 4531/4885POLB 1215/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | TSHR 4027/4885MAPT 4186/4885POLB 2841/4885 |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | TSHR 242/4885MAPT 4678/4885POLB 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.